Literature DB >> 32556194

Indirect effect of oral azithromycin on the gut resistome of untreated children: a randomized controlled trial.

Catherine E Oldenburg1,2,3, Armin Hinterwirth1, Lee Worden1, Ali Sié4, Clarisse Dah4, Lucienne Ouermi4, Boubacar Coulibaly4, Lina Zhong1, Cindi Chen1, Kevin Ruder1, Thomas M Lietman1,2,3, Jeremy D Keenan1,2, Thuy Doan1,2.   

Abstract

BACKGROUND: Antibiotic use by one individual may affect selection for antimicrobial resistance in close contacts. Here we evaluated whether oral antibiotic treatment of one child within a household affected the gut resistome of an untreated cohabiting child.
METHODS: Households with at least two children <5 y of age were randomized in a 1:1 fashion to a 5d course of azithromycin or placebo. To evaluate indirect effects of azithromycin treatment on the gut resistome, we randomly assigned one child in the house to azithromycin and one to placebo. In placebo households, each child received placebo. We performed DNA sequencing of rectal swabs collected 5 d after the last antibiotic dose. We estimated risk ratios for the presence of genetic resistance determinants at the class level using modified Poisson models for children in azithromycin households compared with placebo households and assessed the composition of the resistome using permutational analysis of variance (PERMANOVA).
RESULTS: Of 58 children (n = 30 azithromycin households, n = 28 placebo households) with post-treatment rectal swabs, genetic resistance determinants were common but there was no significant difference at the class (p = 0.54 for macrolides) or gene (p = 0.94 for structure by PERMANOVA, p = 0.94 for diversity) level between untreated children in azithromycin households compared with placebo households.
CONCLUSIONS: The results are encouraging that one child's antibiotic use may not influence the resistome of another child. Trial registration: ClinicalTrials.gov NCT03187834.
© The Author(s) 2020. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.

Entities:  

Keywords:  antimicrobial resistance; azithromycin; randomized controlled trial

Year:  2021        PMID: 32556194      PMCID: PMC7902679          DOI: 10.1093/inthealth/ihaa029

Source DB:  PubMed          Journal:  Int Health        ISSN: 1876-3405            Impact factor:   2.473


  15 in total

1.  Antimicrobial Resistance Following Azithromycin Mass Drug Administration: Potential Surveillance Strategies to Assess Public Health Impact.

Authors:  Ines Mack; Mike Sharland; James A Berkley; Nigel Klein; Surbhi Malhotra-Kumar; Julia Bielicki
Journal:  Clin Infect Dis       Date:  2020-03-17       Impact factor: 9.079

2.  Gut Resistome After Oral Antibiotics in Preschool Children in Burkina Faso: A Randomized, Controlled Trial.

Authors:  Catherine E Oldenburg; Armin Hinterwirth; Ali Sié; Boubacar Coulibaly; Lucienne Ouermi; Clarisse Dah; Charlemagne Tapsoba; Susie L Cummings; Lina Zhong; Cindi Chen; Samarpita Sarkar; Till Bärnighausen; Thomas M Lietman; Jeremy D Keenan; Thuy Doan
Journal:  Clin Infect Dis       Date:  2020-01-16       Impact factor: 9.079

3.  Antibiotic Prescription Patterns among Children Younger than 5 Years in Nouna District, Burkina Faso.

Authors:  Ali Sié; Boubacar Coulibaly; Sawadogo Adama; Lucienne Ouermi; Clarisse Dah; Charlemagne Tapsoba; Till Bärnighausen; John Daniel Kelly; Thuy Doan; Thomas M Lietman; Jeremy D Keenan; Catherine E Oldenburg
Journal:  Am J Trop Med Hyg       Date:  2019-05       Impact factor: 2.345

4.  The Health and Demographic Surveillance System (HDSS) in Nouna, Burkina Faso, 1993-2007.

Authors:  Ali Sié; Valérie R Louis; Adjima Gbangou; Olaf Müller; Louis Niamba; Gabriele Stieglbauer; Maurice Yé; Bocar Kouyaté; Rainer Sauerborn; Heiko Becher
Journal:  Glob Health Action       Date:  2010-09-14       Impact factor: 2.640

5.  Gut microbiome alteration in MORDOR I: a community-randomized trial of mass azithromycin distribution.

Authors:  T Doan; A Hinterwirth; L Worden; A M Arzika; R Maliki; A Abdou; S Kane; L Zhong; S L Cummings; S Sakar; C Chen; C Cook; E Lebas; E D Chow; I Nachamkin; T C Porco; J D Keenan; T M Lietman
Journal:  Nat Med       Date:  2019-08-12       Impact factor: 53.440

6.  The benefits and risks of mass antibiotic use for reducing child mortality.

Authors:  Zulfiqar A Bhutta
Journal:  Nat Med       Date:  2019-09       Impact factor: 53.440

7.  Use of antibiotics in children younger than two years in eight countries: a prospective cohort study.

Authors:  Elizabeth T Rogawski; James A Platts-Mills; Jessica C Seidman; Sushil John; Mustafa Mahfuz; Manjeswori Ulak; Sanjaya K Shrestha; Sajid Bashir Soofi; Pablo Penataro Yori; Estomih Mduma; Erling Svensen; Tahmeed Ahmed; Aldo Am Lima; Zulfiqar A Bhutta; Margaret N Kosek; Dennis R Lang; Michael Gottlieb; Anita Km Zaidi; Gagandeep Kang; Pascal O Bessong; Eric R Houpt; Richard L Guerrant
Journal:  Bull World Health Organ       Date:  2016-11-03       Impact factor: 9.408

8.  Indirect Effect of Azithromycin Use on the Intestinal Microbiome Diversity of Untreated Children: A Randomized Trial.

Authors:  Catherine E Oldenburg; Ali Sié; Boubacar Coulibaly; Lucienne Ouermi; Clarisse Dah; Charlemagne Tapsoba; Till Bärnighausen; Elodie Lebas; Ahmed M Arzika; Susie Cummings; Lina Zhong; Thomas M Lietman; Jeremy D Keenan; Thuy Doan
Journal:  Open Forum Infect Dis       Date:  2019-02-06       Impact factor: 3.835

9.  Macrolide Resistance in MORDOR I - A Cluster-Randomized Trial in Niger.

Authors:  Thuy Doan; Ahmed M Arzika; Armin Hinterwirth; Ramatou Maliki; Lina Zhong; Susie Cummings; Samarpita Sarkar; Cindi Chen; Travis C Porco; Jeremy D Keenan; Thomas M Lietman
Journal:  N Engl J Med       Date:  2019-06-06       Impact factor: 91.245

10.  Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa.

Authors:  Jeremy D Keenan; Robin L Bailey; Sheila K West; Ahmed M Arzika; John Hart; Jerusha Weaver; Khumbo Kalua; Zakayo Mrango; Kathryn J Ray; Catherine Cook; Elodie Lebas; Kieran S O'Brien; Paul M Emerson; Travis C Porco; Thomas M Lietman
Journal:  N Engl J Med       Date:  2018-04-26       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.